Hoyos G L, McEwen J G, Brummer E, Castañeda E, Restrepo A, Stevens D A
Sabouraudia. 1984;22(5):419-26.
In a murine model of chronic pulmonary and disseminated paracoccidioidomycosis, ketoconazole (100 mg kg-1 in 0.3% agar) given by gavage twice daily for 1 or 2 months enabled all mice to clear disseminated Paracoccidioides brasiliensis from the spleen. Clearance of P. brasiliensis from the lungs was more difficult, and was achieved in 60% of the mice treated for 2 months. Sera from agar-treated control mice at days 77 and 103 post-infection demonstrated precipitating antibodies to P. brasiliensis antigens, but sera from ketoconazole-treated mice were precipitin-negative, indicating a favorable prognosis. Delayed hypersensitivity reactions to P. brasiliensis antigens in ketoconazole-treated mice were not significantly greater than in controls; consequently this test correlated less well with response than levels of serum antibody. This is the first use of this animal model of paracoccidioidomycosis to study the effect of antifungal drug protocols on the resolution of the disease. It also demonstrates the utility of this model in addressing clinically relevant questions about this disease and its treatment.
在慢性肺及播散性副球孢子菌病的小鼠模型中,每天经口灌胃给予酮康唑(100毫克/千克,溶于0.3%琼脂),持续1或2个月,所有小鼠脾脏中的播散性巴西副球孢子菌均被清除。清除肺部的巴西副球孢子菌较为困难,接受2个月治疗的小鼠中有60%实现了清除。感染后第77天和第103天,经琼脂处理的对照小鼠血清显示出针对巴西副球孢子菌抗原的沉淀抗体,但酮康唑处理小鼠的血清沉淀反应为阴性,表明预后良好。酮康唑处理小鼠对巴西副球孢子菌抗原的迟发型超敏反应并不比对照组显著增强;因此,该试验与反应的相关性不如血清抗体水平。这是首次使用这种副球孢子菌病动物模型来研究抗真菌药物方案对疾病消退的影响。它还证明了该模型在解决有关这种疾病及其治疗的临床相关问题方面的实用性。